by Damon Race | Jul 23, 2024 | Press
July 23, 2024 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood diseases and disorders, today announced that Sylvia Fong, Ph.D. has joined the Company’s Scientific Advisory Board as the...
by Damon Race | Apr 16, 2024 | In the News
Damon R. Race, President & CEO RALEIGH, N.C., April 16, 2024 /PRNewswire/ — GeneVentiv Therapeutics, developer of GENV-HEM (AAV8.FVa) for all hemophilias, announced today it has been awarded a Direct to Phase II Small Business Innovation Research (SBIR)...
by Damon Race | Mar 26, 2024 | In the News
ReciBioPharm, GeneVentiv to advance GENV-HEM to Phase 1/2 clinical testing by Margarida Maia, PhD | March 15, 2024 ReciBioPharm and GeneVentiv Therapeutics are teaming up to advance the development of GENV-HEM, a gene therapy for all hemophilia patients, including...
by Damon Race | Mar 13, 2024 | Press
March 13 2024 ReciBioPharm, the advanced and emerging therapies business unit of Recipharm, has announced a collaboration agreement with GeneVentiv Therapeutics, a pre-clinical gene therapy company, to advance development of an Adeno-Associated Virus (AAV)-based...
by Damon Race | Jan 30, 2024 | Press
January 30, 2024 Damon R. Race, President & CEO RALEIGH, NC – GeneVentiv Therapeutics, a pre-clinical gene therapy company focused on blood disorders, today announced it will attend the BIO CEO & Investor Conference, which will be held in New York, NY from...
Recent Comments